KNKathleen A. Neville

Kathleen A. Neville

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen A. Neville has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Developmental Changes of Normal Pupil Size and Reactivity in Children

    by Jacob T. Brown, Mark Connelly, Caitlin Nickols, Kathleen A. Neville

    Purpose: The goal of this study was to establish normative values for measurements of quantitative pupillometry in children. Methods: Quantitative pupillometry measurements were obtained from children between 1 and 18 years of age being seen for either a well child check or other outpatient appointment. Results: Maximum and minimum pupil size increased slightly with age; however, the correlation was weak ( r = 0.29 and 0.19, respectively). Similarly weak correlations with age also were observed for maximum constriction velocity ( r = −0.29) and dilation velocity ( r = 0.27). Maximum (5.56 vs 4.97 mm) and minimum (3.74 vs 3.40 mm) pupil sizes were significantly larger in whites than in African Americans. Conclusions: Pupil size and reactivity show little correlation with age and are therefore suitable for further exploration in using pupillometry as a biomarker across the pediatric age range. Differences in race should be taken into consideration when pupillometry is used in mixed populations. [ J Pediatr Ophthalmol Strabismus. 2015:52(3):147–151.]


  • Pharmacokinetics of hydrocodone/acetaminophen combination product in children ages 6-17 with moderate to moderately severe postoperative pain

    by Wei Liu, Sandeep Dutta, Greg Kearns, Walid Awni, Kathleen A. Neville

    Lortab® Elixir, a proprietary combination product containing hydrocodone and acetaminophen, is approved in the US for the treatment of moderate to moderately severe pain in children. Despite this approval, pediatric pharmacokinetic data using this product have not been previously published. Using a single‐dose open‐label study approach, we evaluated the pharmacokinetics, tolerability, and safety of this product in 17 healthy children 6–17 years of age. Results showed that the body weight‐normalized oral clearance (L/h/kg) of hydrocodone and acetaminophen were 42% and 27% higher, respectively when compared to data from healthy adults. This suggests that a higher mg/kg dose would be required in children to achieve exposures similar to adults. We found adjustment of hydrocodone and acetaminophen dose by body surface area to be more optimal than body weight‐based dose adjustments for achieving similar systemic exposure in children and adults. However, body weight‐based hydrocodone and acetaminophen dosing regimens provided close approximation of adult exposures in pediatric patients with approximately 22% to 24% lower hydrocodone and acetaminophen dose/BW‐normalized AUC in pediatric patients compared to adults. Finally, the adverse event profile in our pediatric cohort was consistent with that expected of opioid‐naive subjects receiving opioid‐combination therapy.


  • Pupillometry: a non-invasive technique for pain assessment in paediatric patients

    by M. A. Connelly, Jacob T Brown, Gregory L Kearns, R. A. Anderson, Shawn D St Peter, K. A. Neville

    Objective Pupillometry has been used to assess pain intensity and response to analgesic medications in adults. The aim of this observational study was to explore proof of concept for the use of this technique in paediatric patients. Changes in pupil parameters before and after opioid exposure also were evaluated. Design and setting This was a single-centre, prospective study conducted at an academic paediatric medical centre. Patients Children 9–17 years of age undergoing elective surgical correction of pectus excavatum were enrolled into a protocol approved by the human ethical committee (institutional review board). Interventions Pupil size and reactivity were measured using a handheld pupillometer. Pain was assessed using age-appropriate, validated pain self-report scales. Results Thirty patients were enrolled. Each point change on a 10 cm visual analogue pain intensity scale was associated with a statistically significant mean change of 0.11 mm/s in maximum pupil constriction velocity, and of approximately 0.4% in pupil diameter. As expected, there was an association between total opioid dose (expressed as morphine equivalents) and pupil diameter. Age, sex and baseline anxiety scores did not correlate significantly with pupillary response. Conclusions The association of maximum pupillary constriction velocity and diameter with pain scores illustrates the potential for using pupillometry as a non-invasive method to objectively quantitate pain response/intensity in children. The technique holds promise as a pharmacodynamic ‘tool’ to assess opioid response in paediatric patients.


  • Developmental pharmacogenomics

    by Kathleen A. Neville, Mara L. Becker, Jennifer L. Goldman, Gregory L. Kearns

    Summary: Interindividual variability in the disposition and action associated with similar doses of a given medication is an inherent characteristic of both adult and pediatric populations. Genotype–phenotype relationships in infants and children must take into account the role that ontogeny plays in producing variability in both pharmacokinetics and pharmacodynamics. This review explores pharmacogenomics in the context of ontogeny and relates these to the expression of drug‐metabolizing enzymes and transporters and the consequent effect on the exposure–response relationship in the early years of life.


  • CONTRIBUTORS

    by Darrell R. Abernethy, Viola Andresen, Arthur J. Atkinson, Michel Azizi, Helen L. Baron, Carol L. Beck, Atta Behfar, Rodney Bell, Eduardo E. Benarroch, Neal L. Benowitz, et al.